AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.
Pfizer’s blockbuster rheumatoid arthritis drug Xeljanz has been a strong performer for the company, bringing in $1.77 billion in revenue last year, but now the company has indicated it intends to make a change in a post-marketing study due to safety concerns.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
IFM Therapeutics launched a second subsidiary in less than a year. The Boston-based company launched IFM Due, a subsidiary company developing a suite of cGAS inhibitors and STING antagonists that can target diseases such as NASH, lupus and Parkinson’s.
The Nasdaq indicated that there was a record amount of biotech initial public offerings (IPOs) in 2018, totaling around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
Eli Lilly and Co. said the company’s psoriatic arthritis (PsA) drug Taltz was found to be more effective than the world’s best-selling prescription medicine, AbbVie Inc.’s Humira, in a late-stage study.
People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.
Johnson & Johnson said the company’s drug Tremfya was more effective than Novartis AG’s rival medicine Cosentyx, and met the main goal of a late-stage study in adults with moderate-to-severe plaque psoriasis.
Orchard Therapeutics is developing a suite of autologous ex-vivo lentiviral gene therapies to correct a rare autoimmune disorder.
Janssen’s Stelara Demonstrates Sustained Efficacy in Improving Clinical Remission Rates in Patients with Moderate to Severe Crohn’s Disease Throughout Three Years
The Janssen Pharmaceutical Companies of Johnson & Johnson announced new three-year data from the IM-UNITI study, which demonstrates the continued efficacy of Stelara (ustekinumab) in improving clinical remission rates and shows the drug to be generally well-tolerated in patients with Crohn’s disease.